Main Highlights
- immunitoAI, a biotech startup creating an AI-powered antibody discovery and screening platform, revealed that it had secured $1 million in a seed round.
- According to the official announcement, the startup’s cash will be used for product development and industry collaborations.
- Aridni Shah and Trisha Chatterjee founded immunitoAI in November 2020 to create and screen antibody candidates for a particular antigen.
- They want to use this seed investment to further improve their AI solutions and confirm forecasts through biological studies.
On Wednesday, immunitoAI, a biotech startup creating an AI-powered antibody discovery and screening platform, revealed that it had secured $1 million in a seed round headed by Pi Ventures, with current investor Entrepreneur First also participating. This is the first investment made by pi Ventures from their Fund 2, which was disclosed in April 2021.
According to the official announcement, the startup’s cash will be used for product development and industry collaborations. Aridni Shah and Trisha Chatterjee founded immunitoAI in November 2020 to create and screen antibody candidates for a particular antigen. With this technique, the firm hopes to significantly increase the number of antibodies found, making tailored therapy a standard in the future.
How will immunitoAI utilize the funds?
“Integration of AI with biology has become a reality today,” stated Aridni Shah, CEO, and Co-founder of immunitoAI. Biology has always been tough to study and understand, but with the application of artificial intelligence, we have begun to bridge the gaps, and what was once considered to be impossible has become possible.”
With the aid of technologies, their aim is to make antibody treatment a standard practice. They want to use this seed investment to further improve their AI solutions and confirm forecasts through biological studies. While the near-term focus is on antibody screening and improvement, the firm intends to create its own antibody candidates in the medium and long run.
Antibodies are a great option for Targeted Therapy, but the time and cost involved in finding new antibodies precludes them from being widely utilized as a medicine today. ImmunitoAI aims to overcome this barrier by utilizing Artificial Intelligence to aid in Antibody Discovery and Screening.
The company’s platform provides evolved antibodies, as well as the ability to filter and rank antibodies, allowing healthcare organizations to save time and money while increasing efficiency. However, it goes without saying that AI prediction in Biology must be accompanied by laboratory innovations. The company’s main competency is biological research and validation with a continuous feedback loop between the dry lab and wet lab.
Products by immunitoAI
The firm, which was founded in 2020, has two items. ImRANK is an AI tool that uses artificial intelligence to evaluate and rank known antibody sequences in order to forecast the highest binding strength with a specific antigen of your choosing. ImRANK is now in the research and development phase; the beta version will be released shortly. The second product is imEVOLVE, an AI that finds and mutates areas of antibodies to increase binding affinity with the antigen of your choosing. imEVOLVE is currently in the Conceptual Phase.
immunitoAI is a life sciences (biotech) business that uses artificial intelligence (AI) to transform antibody discovery and treatments. Their full-stack technology, which is poised to expand internationally, forecasts the best therapeutic antibody candidates, saving time by 60%, money by 50%, and tripling efficiency.
Roopan Aulakh, Managing Director of pi Ventures, commented on the investment, saying, “Our goal at pi has been to invest in businesses that are changing sectors through disruptive technologies.” This concept is nicely represented by immunitoAI, our first investment from our newly established Fund II.”
The company’s AI-powered platform will accelerate and reduce the cost of antibody development, allowing tailored treatment for a variety of illnesses. They are excited to collaborate with Aridni and Trisha, who bring a unique blend of biotech and AI to the table.
